Moderna's Q4 Sales Plummet; Company Bets on New Vaccine for 10% Growth by 2026

Humana's Q4 Loss Expands; Medicare Quality Downgrade Signals Sharp 2026 Earnings Decline

Humana reported a wider fourth-quarter loss as medical costs continue to rise and said it expects a sharp decline in 2026 earnings due to lower quality ratings of its Medicare plans.

Markets★★Similarity: 63% · Feb 10

AstraZeneca Confidently Pursues $80 Billion Revenue Target by 2030, Driven by New Medicines

CEO Pascal Soriot said in a call with reporters on Tuesday that the group’s confidence in reaching $80 billion in revenue in 2030 was growing.

Markets★★★Similarity: 63% · Feb 12

Sanofi Stock Dives 5% as Garijo Replaces Hudson Amid Performance Slump

Belen Garijo will succeed Paul Hudson as CEO following a string of clinical setbacks at the drugmaker.

Markets★★Similarity: 62% · Feb 12

Adyen stock plummets after revenue miss and flat 2026 EBITDA margin forecast

Revenue failed to meet consensus expectations and the company forecast flat Ebitda margins growth for the new year.

Moderna's Q4 Sales Plummet; Company Bets on New Vaccine for 10% Growth by 2026

Read More On

Related Articles

Humana's Q4 Loss Expands; Medicare Quality Downgrade Signals Sharp 2026 Earnings Decline

AstraZeneca Confidently Pursues $80 Billion Revenue Target by 2030, Driven by New Medicines

Sanofi Stock Dives 5% as Garijo Replaces Hudson Amid Performance Slump

Adyen stock plummets after revenue miss and flat 2026 EBITDA margin forecast

Moderna's Q4 Sales Plummet; Company Bets on New Vaccine for 10% Growth by 2026

Read More On

Related Articles

Humana's Q4 Loss Expands; Medicare Quality Downgrade Signals Sharp 2026 Earnings Decline

AstraZeneca Confidently Pursues $80 Billion Revenue Target by 2030, Driven by New Medicines

Sanofi Stock Dives 5% as Garijo Replaces Hudson Amid Performance Slump

Adyen stock plummets after revenue miss and flat 2026 EBITDA margin forecast